Drug Target Review – Issue #4 2017
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
List view / Grid view
Articles
Drug patents expire. Can IP data help you prepare?
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
Flow cytometry – accelerating neuroscience research
Flow cytometry continues to evolve at a fast pace and provides neuroscientists with the ability to perform many highly-specialised assays simultaneously. It meets the demands of cutting-edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalogue its molecular or physical features...
Assay development for image-based high-content screening
Image-based high-content screening (HCS) is a high-throughput screening (HTS) technology that combines automated fluorescence microscopy from microtiter plates with digital image analysis. This effectively allows phenotypic screening with sufficient throughput to interrogate large compound libraries...
Structure based drug discovery facilitated by crystallography
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
Expert view: Innovations in 3D
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
EUTCD-Grade lines: an innovative approach to creating and supplying clinical hESC lines
The ever-increasing pressure to turn bench-top discoveries into new therapies has led to the re-purposing of embryonic stem cell lines, originally intended for basic research, for clinical applications...
Expert view: A technological breakthrough in flow cytometry
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
Expert view: Advances in NGS technology
The multiplex and high-throughput capabilities of next-generation sequencing (NGS) allow researchers to study an immense number of DNA/RNA molecules per run, bringing opportunities to study biological or clinical research questions that could not be addressed before...
How next-generation sequencing is opening the door for drug discovery
The Wellcome Trust Sanger Institute's Kim Judge explains how Next Generation Sequencing forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery...
NGS: empowering infectious disease research beyond reality
Pushpanathan Muthuirulan & Pooja Sharma explain how high-throughput next-generation sequencing (NGS) technologies are revolutionising our ability to characterise infectious diseases at genomic, transcriptomic and epigenetic levels...
Expert view: Single-cell sequencing in basic research and clinical applications
Next-generation sequencing (NGS) has greatly increased our understanding of biological phenomena and human disease. In particular, single-cell sequencing is one of the fastest-growing applications...
NGS In-Depth Focus 2017
Next-generation sequencing is a crucial part of the scientist's toolkit. This in-depth focus compares the strengths and weaknesses of a range of NGS technologies and examines the benefits and challenges of using it in infectious disease diagnosis...
Expert view: Overcoming NGS obstacles
Using next-generation sequencing techniques enables pharmaceutical companies to explore the molecular landscape of disease initiation and progression with unprecedented clarity. Dr Sam Rulli, Product Manager at QIAGEN, provides his insight into the major challenges researchers face...
Expert view: The future of single-cell sequencing
The power of single-cell sequencing and its application in the field of oncology remains a top opportunity for discoveries that could have a huge impact on improving human health worldwide. However, barriers remain before those studies can be furthered...
